Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.

October 29, 2013

MINNEAPOLIS, Oct. 29, 2013 /PRNewswire/ — Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Humana, Inc. has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty’s Urgent(®) PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Humana is the sixth largest private insurer in the US with approximately 8.9 million covered lives in 35 states and is also the administrator for Tricare South and several Medicare Advantage plans.

“We are very pleased that Humana has incorporated the Urgent PC Neuromodulation System into their incontinence coverage policy,” said Darin Hammers, Senior Vice President of Sales and Marketing. “This decision will now provide more patients access to the benefits of this clinically and cost-effective therapy. Urgent PC delivers office-based, minimally invasive neuromodulation for OAB patients who are affected by this chronic condition.”

The policy is available on the Humana website at www.humana.com.

About Overactive Bladder

Overactive bladder (OAB) is a chronic condition that affects approximately 34 million US adults. The symptoms include urinary urgency, frequency and urge incontinence. The Urgent PC Neuromodulation System is the only FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in

The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent(®) PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique(®), an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.

    For Further Information:

    Uroplasty, Inc.                       EVC Group
    ---------------                       ---------

    Rob Kill                              Jenifer Kirtland (Investors)

    President and CEO                     415.568.9349

    952.426.6140                          Janine McCargo (Media)

                                          646.688.0425

SOURCE Uroplasty, Inc.


Source: PR Newswire